The study was published September 1 in PLoS Pathogens.
The study emphasizes that health professionals need to record the cryptococcal species more carefully to understand different clinical courses and possibly to change treatment strategies.
Researchers at Duke University Medical Center discovered that in the Los Angeles area, more than 12 percent of AIDS patients diagnosed with Crypotococcus were infected with C. gattii, much higher than earlier studies, which suggested that only about 1 percent have C. gattii. The researchers based these figures on molecular testing of fungal DNA barcodes.
This discovery comes at the same time as a C. gattii outbreak is expanding in the Pacific Northwest, spreading southward from Vancouver, British Columbia, through Washington, Oregon, and into northern California. Molecular testing is helping both health officials and scientists gain a picture of how a formerly tropical fungus could find new territory for infection in temperate climates.
“Importantly, we found that isolates causing the outbreak and those infecting AIDS patients are completely different (VGII vs. VGIII),” said co-lead author Edmond Byrnes, PhD, a recent graduate from the Heitman laboratory.
Wenjun Li, PhD, also a co-lead author and researcher in the Heitman laboratory, noted that, based on the fungal isolate samples taken from patients, those with C. gattii may experience resistance to the commonly used “azole” drugs that combat fungal infections, and clinicians might be better aware of potential treatment problems if they knew the species.
Because cryptococcal strains are responsible for over 620,000 deaths annually and responsible for one-third of all AIDS deaths, this species distinction may be of public health importance.
“There may be an unrecognized health burden in AIDS patients attributable to C. gattii rather than C. neoformans,” Heitman said.
He said that while a simple test is all that is needed to distinguish the two strains, “few clinical microbiology labs or hospitals, even in developed countries, are equipped to distinguish C. neoformans from C. gattii.”
Heitman said that he doesn’t believe that there is any human-to-human transmission of C. gattii, but rather, patients are being exposed in the environment. For example, one AIDS patient from San Diego had an isolate that was traced back to a type of tree, which is a common place to find C. gattii in Australia and elsewhere.
“This study clearly illustrates that AIDS patients in certain areas of the world might be infected by two different cryptococcal species,” said John R. Perfect, MD, professor of medicine at Duke University Medical Center.
“Although the outcome of infection in comparison between the two species remains uncertain, this study shows that we need to carefully control for potential differences and study them further.”
Medical management might be more complicated for C. gattii compared to C. neoformans, including the possibility of azole drug resistance and the formation of cryptococcomas in the central nervous system that can be difficult to treat and that cause abscesses.
“Based on the prevalence we found, it makes sense to pursue further clinical studies, not just to find out the species, but also the molecular type, so we can learn all we can about how this pathogen is travelling and evolving,” Heitman said.
Other authors include co-lead author Yonathan Lewit of Duke Molecular Genetics and Microbiology and Fred S. Dietrich of Duke Molecular Genetics and Microbiology, as well as the Duke Institute for Genome Sciences and Policy; co-lead author Ping Ren, Sudha Chatuverdi and Vishnu Chatuverdi of the Mycology Laboratory at Wadsworth Center in Albany, NY; Kerstin Voelz and Robin C. May of the of the Department of Molecular Pathobiology in the School of Biosciences at the University of Birmingham in the United Kingdom (UK); and James A. Fraser of the Department of Molecular and Microbial Sciences at the University of Queensland, Brisbane, Australia.
The work was supported by the National Institutes of Health, the National Institute for Allergies and Infectious Disease, the Medical Research Council (UK), and funds from the Wadsworth Center Clinical Laboratory Reference System.